VRDN on XNAS, Health Care, Viridian Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue fell 64% last quarter to $25.8M while the stock rose 30% in one month.
BadNet loss of $453.6M over the last 12 months
BadShort interest is 15% of shares, 1.6 times its year-earlier level
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $25.8M, net loss $101.2M.
31 Dec 2021RevenueNet incomeNet losstallest bar $127.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$25.8M
-$101.2M
30 Jun 2026
$284K
-$127.1M
31 Mar 2026
$141K
-$104.9M
31 Dec 2025
$132K
-$120.4M
30 Sep 2025
$70.6M
-$34.6M
30 Jun 2025
$75K
-$100.7M
31 Mar 2025
$72K
-$86.9M
31 Dec 2024
$72K
-$79.7M
30 Sep 2024
$86K
-$76.7M
30 Jun 2024
$72K
-$65.0M
31 Mar 2024
$72K
-$48.5M
31 Dec 2023
$72K
-$66.9M
30 Sep 2023
$72K
-$47.7M
30 Jun 2023
$72K
-$55.1M
31 Mar 2023
$98K
-$68.2M
31 Dec 2022
$105K
-$45.8M
30 Sep 2022
$1.2M
-$28.9M
30 Jun 2022
$256K
-$29.5M
31 Mar 2022
$216K
-$25.7M
31 Dec 2021
$214K
-$28.9M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$26.3M
$70.8M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-63%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$453.6M
-$302.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
-464%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
-427%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-83.7%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$326.3M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$955.2M
$490.9M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$242.5M
$20.9M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$712.7M (net cash)
-$470.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.42
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$5.11
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
129
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
102
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
5.9
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+9.9%
233 13F filers vs 212
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
137.1M shares held by 13F filers (30 Sep 2026) of 113.6M outstanding (2 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
15%
17.0M shares sold short (30 Oct 2026) of 113.6M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
9.1
17.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.3%
18.0M shares sold short in the report before, 17.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
48%
48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-64%
$25.8M vs $70.6M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
24
24 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
12×
24 articles in the last 7 days; its usual week has 2.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 19.0M, 1.6× a year earlier
Price $29.96 on 20 Nov 2026, +1.7% over 12 months (12-month range $13.30 to $33.78)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $19.6M in the last 12 months (the 12 months before: $10.0M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 4 published in the last 12 months, +33% on the 12 months before.Revenue per quarter. Revenue $25.8M in the latest quarter, -64% on a year earlier.Capital spending per quarter. Capital spending $370K in the latest quarter, +191% on a year earlier.Institutional holders (13F filers). 233 13F filers reported holding it in the latest 13F quarter, +40% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Changes and notable records, by the date each became public
26 Aug 2026Short interest and volume change
had 19.0M shares sold short in the 14 Aug 2026 report, 1.6× the same report last year.
Same report last year: 11.8M; its normal report is 10.4M.
See the evidence
This period
19.0M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
10.4M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+3.7
Same report last year
11.8M
History used
2,023 days
the 14 Aug 2026 report24 earlier reportsnormal: 10.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 19.2M shares sold short in the 31 Jul 2026 report, 1.6× the same report last year.
Same report last year: 11.7M; its normal report is 10.4M.
See the evidence
This period
19.2M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
10.4M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+4.3
Same report last year
11.7M
History used
2,009 days
the 31 Jul 2026 report24 earlier reportsnormal: 10.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 64 13F filers open a new position in the quarter ended 31 Dec 2025, 2.2× the same quarter last year.
Same quarter last year: 29; its normal quarter is 19.5.
See the evidence
This period
64 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
19.5
Typical spread (median absolute deviation)
3.5
How far from its usual level
+8.6
Same quarter last year
29
History used
1,826 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 19.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $70.6M for the quarter ended 30 Sep 2025, 821× the same quarter last year.
Same quarter last year: $86K; its normal quarter is $72K.
See the evidence
This period
$70.6M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$72K
Typical spread (median absolute deviation)
$0
How far from its usual level
+70.5
Same quarter last year
$86K
History used
3,470 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $72K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 9.4M shares sold short in the 29 Sep 2023 report, 4.4× the same report last year.
Same report last year: 2.1M; its normal report is 3.2M.
See the evidence
This period
9.4M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
869K
How far from its usual level
+4.9
Same report last year
2.1M
History used
973 days
the 29 Sep 2023 report24 earlier reportsnormal: 3.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.3M shares sold short in the 15 Sep 2023 report, 4.9× the same report last year.
Same report last year: 1.9M; its normal report is 2.9M.
See the evidence
This period
9.3M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
2.9M
Typical spread (median absolute deviation)
630K
How far from its usual level
+6.9
Same report last year
1.9M
History used
959 days
the 15 Sep 2023 report24 earlier reportsnormal: 2.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.5M shares sold short in the 31 Aug 2023 report, 6.6× the same report last year.
Same report last year: 1.4M; its normal report is 2.8M.
See the evidence
This period
9.5M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
663K
How far from its usual level
+6.8
Same report last year
1.4M
History used
944 days
the 31 Aug 2023 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.7M shares sold short in the 15 Aug 2023 report, 3.4× the same report last year.
Same report last year: 2.6M; its normal report is 2.8M.
See the evidence
This period
8.7M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
594K
How far from its usual level
+6.7
Same report last year
2.6M
History used
928 days
the 15 Aug 2023 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.2M shares sold short in the 31 Jul 2023 report, 2.4× the same report last year.
Same report last year: 2.6M; its normal report is 2.7M.
See the evidence
This period
6.2M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
467K
How far from its usual level
+5.1
Same report last year
2.6M
History used
913 days
the 31 Jul 2023 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.5M shares sold short in the 14 Jul 2023 report, 2.8× the same report last year.
Same report last year: 2.6M; its normal report is 2.7M.
See the evidence
This period
7.5M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
348K
How far from its usual level
+9.4
Same report last year
2.6M
History used
896 days
the 14 Jul 2023 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.8M shares sold short in the 30 Jun 2023 report, 2.9× the same report last year.
Same report last year: 2.3M; its normal report is 2.6M.
See the evidence
This period
6.8M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
288K
How far from its usual level
+9.6
Same report last year
2.3M
History used
882 days
the 30 Jun 2023 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.1M shares sold short in the 15 Jun 2023 report, 3.5× the same report last year.
Same report last year: 1.7M; its normal report is 2.6M.
See the evidence
This period
6.1M (the 15 Jun 2023 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
281K
How far from its usual level
+8.3
Same report last year
1.7M
History used
867 days
the 15 Jun 2023 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.7M shares sold short in the 31 May 2023 report, 3.8× the same report last year.
Same report last year: 1.5M; its normal report is 2.6M.
See the evidence
This period
5.7M (the 31 May 2023 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
284K
How far from its usual level
+7.4
Same report last year
1.5M
History used
852 days
the 31 May 2023 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.4M shares sold short in the 15 May 2023 report, 3.3× the same report last year.
Same report last year: 1.3M; its normal report is 2.5M.
See the evidence
This period
4.4M (the 15 May 2023 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
278K
How far from its usual level
+4.5
Same report last year
1.3M
History used
836 days
the 15 May 2023 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires on an 8-K with item 5.02 after 90 days without one.
Showing the newest 40 of 102 entries; narrow the window or the kind of data to see older ones.
Not listed: 195 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001590750
Ticker
VRDN
Domain
viridiantherapeutics.com
Employer name
Viridian Therapeutics, Inc. (1 unverified)
Fein
47-1187261 (1 unverified)
Hq location
MA|WALTHAM|02453 (1 unverified)
Name
MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., Viridian Securities Corporation, Viridian Therapeutics Europe Limited and 2 more
Uei
U2XJTSKPT4G3
DOL H-1B labor condition applications and PERM certifications25 data points7 Apr 2025 to 24 Aug 2026
SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)222 records16 Mar 2016 to 9 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)837 data points31 Dec 2012 to 2 Nov 2026
SEC Form 4 insider transactions40 records, 148 data points24 Feb 2017 to 20 Aug 2026
FINRA short interest (twice monthly)414 data points29 Jan 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2936 data points20 Jan 2021 to 20 Nov 2026